Stock Analysis
Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis
Iovance Biotherapeutics, Inc. (IOVA) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Iovance Biotherapeutics, Inc. (IOVA) currently has an AIQ Score of 35/100, indicating a bearish setup. Sentiment is the strongest factor at 66/100. Quality is the weakest current factor at 30/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
IOVA at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $8.48 |
| AIQ Score | 35/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Sell |
| Market Cap | $3.7B |
| P/E Ratio (TTM) | -11.83 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | -$0.11 |
| Revenue (quarter ended 2026-06-30) | $99.31M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.7 |
| Volume | 31.2M |
| 52-week range | $1.76-$15.37 |
| RSI 14 | 26.18 |
| 50-Day SMA | $11.38 |
| 200-Day SMA | $5.81 |
| Analyst Price Target | $12.31 |
| Next Earnings | Nov 5, 2026 |
IOVAIovance Biotherapeutics, Inc.
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum30
- Value34
- Quality30
- Risk resilience53
- Sentiment66
IOVA Stock Analysis Summary
Iovance Biotherapeutics, Inc. (IOVA) currently has an AIQ Score of 35/100, indicating a bearish setup. Sentiment is the strongest factor at 66/100. Quality is the weakest current factor at 30/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, IOVA has AIQ Score of 35/100 with Sentiment base of 66/100 and fading Quality at 30/100. Wait for component alignment before adding exposure.
Sentiment (66/100) leads while Quality (30/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -11.30% stock move · IOVA classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is IOVA Bullish or Bearish Right Now?
IOVA currently has a bearish overall setup. Sentiment is the strongest factor at 66/100, while Momentum is weakest at 30/100. The current evidence suggests a defensive setup.
- - Analyst target implies +45.17% upside from the latest quote.
- - Value is the current constraint at 34/100.
- - Momentum is weak at 30/100.
- - Technical consensus has more sell votes than buy votes (31 vs 12).
Current Consensus
IOVA's Technical Analysis Consensus is currently Sell, with 12 buy, 2 neutral, and 31 sell votes. IOVA's 14-day RSI is 26.18, which places the stock in an oversold momentum range. IOVA's beta is 0.7, indicating lower market sensitivity than the broad market.
What Changed in IOVA?
The largest recent change in IOVA is Momentum moving down by 31.0 points over the available 7-day comparison window. Sentiment remains the strongest visible factor.
What Would Change the IOVA Outlook?
The current bearish outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
IOVA Decision Framework
Public evidence layers, setup checks, and risk context for Iovance Biotherapeutics, Inc..
Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis
Iovance Biotherapeutics, Inc. has an AIQ Score of 35/100 in a Defensive regime. Sentiment is strongest at 66/100. Beta is 0.76, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | IOVA is in a Defensive AIQ regime with score 35/100. |
| Signal Conflict | The primary conflict is that sentiment leads at 66/100 while momentum lags at 30/100. |
| Factor Evidence | Momentum 30/100 · Value 34/100 · Quality 30/100 · Risk 53/100 · Sentiment 66/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Sentiment is the strongest factor at 66/100.
Momentum is 30/100 and RSI (14) is 26.2.
IOVA is in a Defensive regime at 35/100.
Risk factor is 53/100 with beta 0.76 and annual volatility 110.75%.
Current conflict: sentiment leads at 66/100 while momentum lags at 30/100.
IOVA Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
IOVA Fundamentals
IOVA valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
IOVA Technical Analysis
IOVA technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
IOVA Stock Catalysts
Track IOVA earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
IOVA Dividend Analysis
IOVA dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
IOVA Financial Data
IOVA revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
IOVA Risk Analysis
IOVA volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
IOVA Stock News
IOVA stock news, market tone, recent headlines, and catalyst context.
IOVA vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: IOVA · ITCI · KPTI · LEGN · MRVI. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| IOVA Current stock | 35/100 | 34/100 | 30/100 | 53/100 | 1.92 | 110.75% | Current |
| ITCI Intra-Cellular Therapies | 54/100 | 34/100 | — | 82/100 | — | — | IOVA vs ITCI |
| KPTI Karyopharm Therapeutics | 68/100 | 65/100 | 53/100 | 32/100 | -0.43 | 148.28% | IOVA vs KPTI |
| LEGN Legend Biotech | 59/100 | 54/100 | 80/100 | 45/100 | -0.18 | 75.68% | IOVA vs LEGN |
| MRVI Maravai LifeSciences | 45/100 | 34/100 | 72/100 | 46/100 | 1.75 | 69.10% | IOVA vs MRVI |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 29, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts4 recent quarterly periods are available for review.
Checked Oct 31, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching IOVA
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for IOVA
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
IOVA Stock FAQ
What is IOVA stock price today?
Iovance Biotherapeutics, Inc.'s current stock price is $8.48. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is IOVA bullish or bearish right now?
IOVA's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is IOVA's market cap?
IOVA's market cap is $3.7B based on the latest completed market-close snapshot from Oct 30, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is IOVA's current P/E ratio?
IOVA's current P/E ratio is -11.83 based on the latest completed market-close snapshot from Oct 30, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is IOVA's RSI?
IOVA's 14-day RSI is 26.18 based on the latest completed market-close snapshot from Oct 30, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is IOVA above its 50-day and 200-day moving averages?
IOVA is -16.00% from its 50-day SMA and 64.66% from its 200-day SMA based on the latest completed market-close snapshot from Oct 30, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is IOVA's next earnings date?
IOVA's next earnings date is currently listed as Nov 5, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does IOVA pay a dividend?
IOVA's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 30, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.